share_log

Cowen & Co. Upgrades Takeda Pharmaceutical to Outperform, Raises Price Target to $24

Cowen & Co. Upgrades Takeda Pharmaceutical to Outperform, Raises Price Target to $24

Cowen & Co.将武田制药上调至跑赢大盘,将目标股价提高至24美元
Benzinga Real-time News ·  2022/07/19 07:54

Cowen & Co. analyst Ken Cacciatore upgrades Takeda Pharmaceutical (NYSE:TAK) from Market Perform to Outperform and raises the price target from $21 to $24.

Cowen & Co. 分析师肯·卡恰托雷将武田制药(纽约证券交易所代码:TAK)从市场表现上调至跑赢大盘,并将目标股价从21美元上调至24美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发